BioCentury
ARTICLE | Clinical News

Aeterna starts Phase III

May 4, 2000 7:00 AM UTC

Aeterna (TSE:AEL) began Phase III testing of its Neovastat antiangiogenic agent in 270 patients with progressive renal cell carcinoma who have failed standard therapy. The trial in North America and E...